Charles River Laboratories acquires Celsis International
Celsis produces quality control testing in the biopharmaceutical and consumer products industries. Celsis’ systems are principally used for product-release testing to help ensure the safe manufacture of drugs and consumer products.
Celsis complements Charles River’s Endotoxin and Microbrial Detection (EMD) business, bringing CRL access to the consumer products market and expanding its quality control testing solutions across both sterile and non-sterile applications. The acquisition is expected to nearly double the market opportunity for EMD testing products and services.
Charles River Laboratories provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The company provides its clients a broad suite of products and services that improve and expedite the discovery, early-stage development and safe manufacture of new therapies.